- Home
- VTVT vs COEP Comparison
VTVT vs COEP Comparison
Compare VTVT & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- COEP
- Stock Information
- Founded
- VTVT 2015
- COEP 2017
- Country
- VTVT United States
- COEP United States
- Employees
- VTVT N/A
- COEP N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTVT Health Care
- COEP Health Care
- Exchange
- VTVT Nasdaq
- COEP Nasdaq
- Market Cap
- VTVT 38.8M
- COEP 32.4M
- IPO Year
- VTVT 2015
- COEP N/A
- Fundamental
- Price
- VTVT $20.20
- COEP $10.52
- Analyst Decision
- VTVT Strong Buy
- COEP
- Analyst Count
- VTVT 1
- COEP 0
- Target Price
- VTVT $35.00
- COEP N/A
- AVG Volume (30 Days)
- VTVT 8.9K
- COEP 108.7K
- Earning Date
- VTVT 03-12-2025
- COEP 03-25-2025
- Dividend Yield
- VTVT N/A
- COEP N/A
- EPS Growth
- VTVT N/A
- COEP N/A
- EPS
- VTVT N/A
- COEP N/A
- Revenue
- VTVT $1,000,000.00
- COEP N/A
- Revenue This Year
- VTVT N/A
- COEP N/A
- Revenue Next Year
- VTVT N/A
- COEP N/A
- P/E Ratio
- VTVT N/A
- COEP N/A
- Revenue Growth
- VTVT 11011.11
- COEP N/A
- 52 Week Low
- VTVT $8.10
- COEP $2.31
- 52 Week High
- VTVT $30.99
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- VTVT 63.15
- COEP 48.65
- Support Level
- VTVT $19.02
- COEP $9.27
- Resistance Level
- VTVT $20.89
- COEP $12.95
- Average True Range (ATR)
- VTVT 1.15
- COEP 1.59
- MACD
- VTVT 0.30
- COEP -0.33
- Stochastic Oscillator
- VTVT 68.18
- COEP 38.56
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.